Enanta Pharmaceuticals Files 8-K
Ticker: ENTA · Form: 8-K · Filed: Nov 25, 2024 · CIK: 1177648
| Field | Detail |
|---|---|
| Company | Enanta Pharmaceuticals Inc (ENTA) |
| Form Type | 8-K |
| Filed Date | Nov 25, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, sec-filing
Related Tickers: ENNT
TL;DR
Enanta Pharma filed an 8-K on Nov 25, 2024, updating on financials.
AI Summary
On November 25, 2024, Enanta Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well as financial statements and exhibits. No specific financial figures or significant events were detailed in the provided excerpt.
Why It Matters
This filing indicates Enanta Pharmaceuticals is providing updates on its financial performance and condition to the SEC, which is important for investors to monitor.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report for operational and financial updates, with no immediate indication of significant risk or negative events in the provided text.
Key Players & Entities
- Enanta Pharmaceuticals, Inc. (company) — Registrant
- November 25, 2024 (date) — Date of earliest event reported
- 001-35839 (company) — SEC File Number
- 04-3205099 (company) — IRS Employer Identification No.
- 4 Kingsbury Avenue (location) — Principal Executive Offices
- Watertown, Massachusetts (location) — Principal Executive Offices
- 02472 (location) — Principal Executive Offices Zip Code
- (617) 607-0800 (phone) — Registrant's Telephone Number
FAQ
What is the primary purpose of this 8-K filing by Enanta Pharmaceuticals?
The filing is a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, concerning the company's results of operations and financial condition, as well as financial statements and exhibits.
On what date was this 8-K report filed or reported as of?
The report's date of earliest event reported is November 25, 2024.
What is Enanta Pharmaceuticals' principal executive office address?
The principal executive offices are located at 4 Kingsbury Avenue, Watertown, Massachusetts, 02472.
What is Enanta Pharmaceuticals' telephone number?
The registrant's telephone number, including area code, is (617) 607-0800.
What is Enanta Pharmaceuticals' SEC File Number?
Enanta Pharmaceuticals' SEC File Number is 001-35839.
Filing Stats: 448 words · 2 min read · ~1 pages · Grade level 11.8 · Accepted 2024-11-25 16:05:41
Key Financial Figures
- $0.01 — ch registered Common Stock, par value $0.01 per share ENTA Nasdaq Global Select
Filing Documents
- enta-20241125.htm (8-K) — 41KB
- enta-ex99_1.htm (EX-99.1) — 232KB
- img152620751_0.jpg (GRAPHIC) — 16KB
- 0000950170-24-130553.txt ( ) — 443KB
- enta-20241125.xsd (EX-101.SCH) — 40KB
- enta-20241125_htm.xml (XML) — 6KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On November 25, 2024, Enanta Pharmaceuticals, Inc. announced via press release its results for the fiscal quarter and year-ended September 30, 2024. A copy of Enanta's press release is hereby furnished to the Commission and incorporated by reference herein as Exhibit 99.1.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. Exhibit Number Description 99.1 Press Release of Enanta Pharmaceuticals, Inc. dated November 25, 2024, reporting Enanta's financial results for the fiscal quarter and year-ended September 30, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. ENANTA PHARMACEUTICALS, INC. Date: November 25, 2024 By: /s/ Paul J. Mellett Paul J. Mellett Chief Financial and Administrative Officer